Evidence map›Paper›PMID 25863355›Full record

ArticleBrain : a journal of neurology2015

Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis.

Khaled Abdel-Aziz, Torben Schneider, Bhavana S Solanky, Marios C Yiannakas, Dan R Altmann, Claudia A M Wheeler-Kingshott, Amy L Peters, Brian L Day, Alan J Thompson, Olga Ciccarelli

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Advanced Diffusion MR Imaging for Multiple Sclerosis in the Brain and Spinal Cord.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2022
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Advances in spinal cord imaging in multiple sclerosis.Therapeutic advances in neurological disorders · 2019
    Review
  17. Article
  18. Review
  19. Novel Biomarkers of Human GM1 Gangliosidosis Reflect the Clinical Efficacy of Gene Therapy in a Feline Model.Molecular therapy : the journal of the American Society of Gene Therapy · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Khaled Abdel-Aziz1 NMR Research Unit, UCL Institute of Neurology, London, UK 2 Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, London, UK k.abdel-aziz@ucl.ac.uk.
Torben Schneider1 NMR Research Unit, UCL Institute of Neurology, London, UK 3 Department of Neuroinflammation, UCL Institute of Neurology, London, UK.
Bhavana S Solanky1 NMR Research Unit, UCL Institute of Neurology, London, UK 3 Department of Neuroinflammation, UCL Institute of Neurology, London, UK.
Marios C Yiannakas1 NMR Research Unit, UCL Institute of Neurology, London, UK 3 Department of Neuroinflammation, UCL Institute of Neurology, London, UK.
Dan R Altmann1 NMR Research Unit, UCL Institute of Neurology, London, UK 4 Medical Statistics Department, London School of Hygiene and Tropical Medicine, London, UK.
Claudia A M Wheeler-Kingshott1 NMR Research Unit, UCL Institute of Neurology, London, UK 3 Department of Neuroinflammation, UCL Institute of Neurology, London, UK.
Amy L Peters5 Sobell Department, UCL Institute of Neurology, London, UK.
Brian L Day5 Sobell Department, UCL Institute of Neurology, London, UK.
Alan J Thompson1 NMR Research Unit, UCL Institute of Neurology, London, UK 2 Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, London, UK 6 National Institute of Health Research, University College London Hospitals, Biomedical Research Centre, London, UK.
Olga Ciccarelli1 NMR Research Unit, UCL Institute of Neurology, London, UK 2 Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, London, UK 6 National Institute of Health Research, University College London Hospitals, Biomedical Research Centre, London, UK.
University College London · GBLondon School of Hygiene & Tropical Medicine · GBSobell House · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spinal neurodegeneration is an important determinant of disability progression in patients with primary progressive multiple sclerosis. Advanced imaging techniques, such as single-voxel (1)H-magnetic resonance spectroscopy and q-space imaging, have increased pathological specificity for neurodegeneration, but are challenging to implement in the spinal cord and have yet to be applied in early primary progressive multiple sclerosis. By combining these imaging techniques with new clinical measures, which reflect spinal cord pathology more closely than conventional clinical tests, we explored the potential for spinal magnetic resonance spectroscopy and q-space imaging to detect early spinal neurodegeneration that may be responsible for clinical disability. Data from 21 patients with primary progressive multiple sclerosis within 6 years of disease onset, and 24 control subjects were analysed. Patients were clinically assessed on grip strength, vibration perception thresholds and postural stability, in addition to the Expanded Disability Status Scale, Nine Hole Peg Test, Timed 25-Foot Walk Test, Multiple Sclerosis Walking Scale-12, and Modified Ashworth Scale. All subjects underwent magnetic resonance spectroscopy and q-space imaging of the cervical cord and conventional brain and spinal magnetic resonance imaging at 3 T. Multivariate analyses and multiple regression models were used to assess the differences in imaging measures between groups and the relationship between magnetic resonance imaging measures and clinical scores, correcting for age, gender, spinal cord cross-sectional area, brain T2 lesion volume, and brain white matter and grey matter volume fractions. Although patients did not show significant cord atrophy when compared with healthy controls, they had significantly lower total N-acetyl-aspartate (mean 4.01 versus 5.31 mmol/l, P = 0.020) and glutamate-glutamine (mean 4.65 versus 5.93 mmol/l, P = 0.043) than controls. Patients showed an increase in q-space imaging-derived indices of perpendicular diffusivity in both the whole cord and major columns compared with controls (P < 0.05 for all indices). Lower total N-acetyl-aspartate was associated with higher disability, as assessed by the Expanded Disability Status Scale (coefficient = -0.41, 0.01 < P < 0.05), Modified Ashworth Scale (coefficient = -3.78, 0.01 < P < 0.05), vibration perception thresholds (coefficient = -4.37, P = 0.021) and postural sway (P < 0.001). Lower glutamate-glutamine predicted increased postural sway (P = 0.017). Increased perpendicular diffusivity in the whole cord and columns was associated with increased scores on the Modified Ashworth Scale, vibration perception thresholds and postural sway (P < 0.05 in all cases). These imaging findings indicate reduced structural integrity of neurons, demyelination, and abnormalities in the glutamatergic pathways in the cervical cord of early primary progressive multiple sclerosis, in the absence of extensive spinal cord atrophy. The observed relationship between imaging measures and disability suggests that early spinal neurodegeneration may underlie clinical impairment, and should be targeted in future clinical trials with neuroprotective agents to prevent the development of progressive disability.

Indexed as

AdolescentAdultAgedAspartic AcidAtrophyBrainCase-Control StudiesCervical CordDisability EvaluationEarly DiagnosisFemaleGlutamic AcidGlutamineGray MatterHumansMagnetic Resonance ImagingAspartic AcidGlutamic AcidGlutamineN-acetylaspartatebiomarkerscellular mechanismsmultiple sclerosis imaging

Identifiers

PMID25863355
PMCPMC4614136
OpenAlexW2156182571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.